How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: AGTR1

    Description: "angiotensin II receptor, type 1"

    Entrez Gene ID: 185

    SwissProt Acc Number: P30556

    RefSeq: NM_000685

    It was suspected to be CHD related:

    .."These findings suggest that variation in the ACE and AGTR1 genes and their interaction may not only contribute to susceptibility of coronary artery disease as previously found but also modify the disease process, thus contributing to interindividual differences in severity of the disease."..

    From PMID: 12975417, in Journal Heart , 2003


    References

    There were 15 potential papers with AGTR1 and CHD.

    PMIDTitleJournalsDetails
    22782431 "Meta-analysis of the association between angiotensin II receptor, type 1 gene A1166C polymorphism and coronary artery disease in Chinese populations."Journal of the renin-angiotensin-aldosterone system : JRAASMore Details
    22739771 Genetic variation in the renin-angiotensin-aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease.Journal of human hypertensionMore Details
    22307319 Angiotensin converting enzyme gene polymorphism is associated with severity of coronary artery disease in men with high total cholesterol levels.Journal of applied geneticsMore Details
    22508051 Renin-angiotensin-aldosterone system gene polymorphisms and coronary artery disease: detection of gene-gene and gene-environment interactions.Cellular physiology and biochemistry : international journal of experimentalMore Details
    21657802 Influence of renin-angiotensin system gene polymorphisms on the risk of ST-segment-elevation myocardial infarction and association with coronary artery disease risk factors.Molecular diagnosis & therapyMore Details
    21658281 GWAS for discovery and replication of genetic loci associated with sudden cardiac arrest in patients with coronary artery disease.BMC cardiovascular disordersMore Details
    20732682 "A1166C genetic variation of the angiotensin II type I receptor gene and susceptibility to coronary heart disease: collaborative of 53 studies with 20,435 cases and 23,674 controls."AtherosclerosisMore Details
    19948975 Integrative predictive model of coronary artery calcification in atherosclerosis.CirculationMore Details
    18787507 Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes.Pharmacogenetics and genomicsMore Details
    17531579 Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).The American journal of cardiologyMore Details
    17921131 Genetic polymorphisms contribute to acute kidney injury after coronary artery bypass grafting.The heart surgery forumMore Details
    17519002 Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age.BMC medical geneticsMore Details
    15863668 Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits.Journal of medical geneticsMore Details
    16296949 Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis.PharmacogenomicsMore Details
    15193960 Ethnic differences of coronary artery disease-associated SNPs in two Israeli healthy populations using MALDI-TOF mass spectrometry.Life sciencesMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 21 unique genes interacted with AGTR1. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    ZBTB16 Two-hybrid14657020 No
    ADRBK1 Affinity Capture-Western9211925|8662816 CHD related
    GRK5 Affinity Capture-Western9211925|8662816 CHD related
    BDKRB2 Co-fractionation10993080 CHD related
    AGTRAP Reconstituted Complex11733189 No
    TRAF3 Affinity Capture-Western11226259 No
    MAPK1 Affinity Capture-Western11226259 CHD related
    ARRB2 Affinity Capture-Western11226259 No
    ADRBK2 in vivo8662816 No
    RAF1 in vitro;in vivo8753867 CHD related
    ARRB1 in vivo11579203 No
    EGFR in vitro12522132 CHD related
    THOP1 in vitro;yeast 2-hybrid15376229 No
    RAB5A Reconstituted Complex11682489|11682489 No
    AGT in vivo15930094 CHD related
    PLCG1 in vivo9516477 CHD related
    HRAS in vitro;in vivo8753867 No
    GPRASP1 in vitro15452121 No
    JAK2 in vivo7746328 CHD related
    NOS3 in vitro10510297 CHD related
    DNAJC14 in vitro12446598 No


    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00177Valsartan"May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors."C09CA03
    approvedDB00275OlmesartanFor the treatment of hypertension.C09CA08
    approvedDB00678Losartan"May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors."C09CA01
    approvedDB00796Candesartan"May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors."C09CA06
    approvedDB00876Eprosartan"For the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors)."C09CA02
    approvedDB00966Telmisartan"Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors)."C09CA07
    approvedDB01029Irbesartan"For the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure."C09CA04
    approvedDB01342ForasartanFor the treatment of hypertension.
    approvedDB01347SaprisartanSaprisartan is used in the treatment of hypertension and heart failure.
    approvedDB01349TasosartanTasosartan is infrequently in the treatment of hypertension and heart failure.C09CA05